Structure

InChI Key WYWHKKSPHMUBEB-UHFFFAOYSA-N
Smile Nc1nc2[nH]cnc2c(=S)[nH]1
InChI
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)

Physicochemical Descriptors

Property Name Value
Molecular Formula C5H5N5S
Molecular Weight 167.2
AlogP 0.6
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 0.0
Polar Surface Area 83.38
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 11.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA inhibitor FDA
Primary Target
inosine monophosphate dehydrogenase 1
inosine monophosphate dehydrogenase 2

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Brain Neoplasms 3 D001932 ClinicalTrials
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 D054218 ClinicalTrials
Leukemia, Basophilic, Acute 3 D015471 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Myeloproliferative Disorders 3 D009196 ClinicalTrials
Leukemia, Biphenotypic, Acute 3 D015456 ClinicalTrials
Leukemia, Erythroblastic, Acute 3 D004915 ClinicalTrials
Leukemia, Monocytic, Acute 3 D007948 ClinicalTrials
Leukemia, Myelomonocytic, Acute 3 D015479 ClinicalTrials
Leukemia, Megakaryoblastic, Acute 3 D007947 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Anemia, Refractory 3 D000753 ClinicalTrials
Anemia, Refractory, with Excess of Blasts 3 D000754 ClinicalTrials
Brain Neoplasms 3 D001932 ClinicalTrials
Leukemia, Myelomonocytic, Chronic 3 D015477 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Leukemia, Lymphoid 2 D007945 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Histiocytosis, Langerhans-Cell 2 D006646 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials

Related Entries

Scaffolds

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
21.43
Infections and infestations
21.43
Blood and lymphatic system disorders
16.67
Vascular disorders
11.9
Renal and urinary disorders
9.52
Gastrointestinal disorders
4.76
Investigations
4.76
Respiratory, thoracic and mediastinal disorders
4.76
Injury, poisoning and procedural complications
2.38
Reproductive system and breast disorders
2.38

Cross References

Resources Reference
ChEBI 9555
ChEMBL CHEMBL727
DrugBank DB00352
DrugCentral 2632
EPA CompTox DTXSID6023652
FDA SRS WIX31ZPX66
Human Metabolome Database HMDB0014496
Guide to Pharmacology 6845
KEGG C07648
PDB DX4
PharmGKB PA451663
PubChem 91669166
SureChEMBL SCHEMBL3701
ZINC ZINC000006382803